RenovoRx RNXT
NASDAQ RNXT
$1.58 +0.03 (+1.94%)
At close: Oct 2, 2026 · 4:00 PM EDT

RenovoRx (RNXT) Gains from Sales and Divestitures (2026)

Updated

RenovoRx (RNXT) reported Gains from Sales and Divestitures of -$2,000 for Q2 2026.

Analysis

RenovoRx (RNXT) Gains from Sales and Divestitures (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 242.18 Bn 221.33 Bn 4.88 Bn
2 Abbott Laboratories 168.71 Bn 139.79 Bn 7.27 Bn
3 Danaher 150.46 Bn 134.27 Bn 3.61 Bn
4 Intuitive Surgical 138.71 Bn 118.26 Bn 1.96 Bn
5 Medtronic 110.54 Bn 76.41 Bn 6.34 Bn
6 Stryker 105.66 Bn 91.78 Bn 4.50 Bn
7 Boston Scientific 61.74 Bn 56.75 Bn 3.85 Bn
8 Edwards Lifesciences 49.09 Bn 33.21 Bn 1.35 Bn
9 Becton Dickinson 48.16 Bn 45.31 Bn 2.32 Bn
10 RenovoRx 71.29 Mn 71.29 Mn 766,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2,000.00
API Access

RenovoRx Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RNXT&period=max&api_key=YOUR_API_KEY